|
1. Biologie
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
Exploring cancer metabolism [MIT News]
|
|
|
|
|
|
“If
one wants to develop drugs that target metabolism, one really needs to
focus on the context in which it’s happening, which is the environment
of the cell plus the genetics of the cell,” he says. “That is what
defines the sensitivity to drugs.”
|
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
Y-mAbs Plans IPO to Advance Two Pediatric Cancer Drugs to the FDA [Xconomy]
|
|
|
|
|
|
Y-mAbs,
founded in 2015, is led by CEO Claus Juan Møller San Pedro, who was a
co-founder of Danish biotech Genmab. The Y-mAbs cancer drugs were
licensed from Memorial Sloan Kettering Cancer Center in New York, which
stands to gain milestone payments as the drugs progress, and royalties
from sales if any of them are approved.
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.6 Publications
|
|
|
|
|
|
|
|
|
6.9 Controverses
|
|
|